The Masonic Medical Research Laboratory (MMRL) was founded in 1958 by the Grand Lodge of the State of New York.   It is an entity of the Grand Lodge of the State of New York with its 15 Directors being appointed serially by the Grand Master and elected by the Grand Lodge of the State of New York at its annual convocation. Originally established by the Grand Lodge of New York,  the forerunner of the MMRL was known as The Masonic Foundation for Health and Human Welfare and it played a major role in the defeat of rheumatic fever. The MMRL’s current focus is on Cardiovascular Disease, principally focused on Cardiac Arrhythmias and Sudden Death syndrome, including Sudden Infant Death Syndrome (SIDS).  It’s newest venture is into Tissue and Organ Bioengineering with the goal of building new hearts for transplantation.  In recent years, Masonic jurisdictions  of many states have joined with the  Grand Lodge of the State of New York to further its important humanitarian work.
The Laboratory is administered by a Board of Directors and the Executive Director. The Board of Directors consists of up to 15 distinguished Freemasons elected to three-year terms. Their selection is based upon their outstanding business and professional experience. They all serve the Laboratory without compensation.
Mission Statement
The Masonic Medical Research Laboratory is a not-for-profit institute dedicated to improving the health and quality of life for all. The Laboratory’s primary mission is to conduct high quality basic and clinical research aimed at generating knowledge and information necessary for development of the medical cures and treatments of tomorrow. The Laboratory is also committed to providing education and training to basic scientists, clinical researchers and students who will perpetuate and extend the fight against disease.
Vision Statement
To be regarded as a world-leader in medical research, dedicated to generating the knowledge necessary to develop innovative solutions to medical challenges facing society and providing a creative environment for the education and training of the innovators of tomorrow.
Recent 2014 publications ( Not including book chapters or abstracts )
Pathmanathan P; Shotwell MS; Gavaghan DJ; Cordeiro JM; Gray RA, 2015. Uncertainty quantification of fast sodium current steady-state inactivation for multi-scale models of cardiac electrophysiology.  Prog Biophys Mol Biol 117(1):4-18
Burashnikov A; Diego JM; Goodrow RJ Jr; Belardinelli L; Antzelevitch C, 2015. Atria are More Sensitive Than Ventricles to GS-458967-Induced Inhibition of Late Sodium Current.  J Cardiovasc Pharmacol Ther.
Burashnikov A; Belardinelli L; Antzelevitch C, 2015. Inhibition of IKr potentiates development of atrial-selective INa block leading to effective suppression of atrial fibrillation.  Heart Rhythm12(4):836-44
Boczek NJ; Miller EM; Ye D; Nesterenko VV; Tester DJ; Antzelevitch C; Czosek RJ; Ackerman MJ; Ware SM, 2015. Novel Timothy syndrome mutation leading to increase in CACNA1C window current.  Heart Rhythm 12(1):211-9
Obeyesekere MN; Antzelevitch C; Krahn AD, 2015. Management of ventricular arrhythmias in suspected channelopathies.  Circ Arrhythm Electrophysiol 8(1):221-31
Liang J; Yuan X; Shi S; Wang F; Chen Y; Qu C; Chen J; Hu D; Yang B, 2015. Effect and mechanism of fluoxetine on electrophysiology in vivo in a rat model of postmyocardial infarction depression. Drug Des Devel Ther 9:763-72

Betzenhauser MJ; Pitt GS; Antzelevitch C, 2015. Calcium Channel Mutations in Cardiac Arrhythmia Syndromes.  Curr Mol Pharmacol.

Cordeiro JM; Zeina T; Goodrow R; Kaplan AD; Thomas LM; Nesterenko VV; Treat JA; Hawel L 3rd; Byus C; Bett GC; Rasmusson RL; Panama BK, 2015. Regional variation of the inwardly rectifying potassium current in the canine heart and the contributions to differences in action potential repolarization.  J Mol Cell Cardiol 84:52-60
Giustetto C; Scrocco C; Schimpf R; Maury P; Mazzanti A; Levetto M; Anttonen O; Dalmasso P; Cerrato N; Gribaudo E; Wolpert C; Giachino D; Antzelevitch C; Borggrefe M; Gaita F, 2015.Usefulness of exercise test in the diagnosis of short QT syndrome.  Europace 17(4):628-34
Tan BY; Yong RY; Barajas-Martinez H; Dumaine R; Chew YX; Wasan PS; Ching CK; Ho KL; Gan LS; Morin N; Chong AP; Yap SH; Neo JL; Yap EP; Moochhala S; Chong DT; Chow W; Seow SC; Hu D; Uttamchandani M; Teo WS, 2015. A Brugada syndrome proband with compound heterozygote SCN5A mutations identified from a Chinese family in Singapore.  Europace.
Hasdemir C; Payzin S; Kocabas U; Sahin H; Yildirim N; Alp A; Aydin M; Pfeiffer R; Burashnikov E; Wu Y; Antzelevitch C, 2015. High prevalence of concealed Brugada syndrome in patients with atrioventricular nodal reentrant tachycardia.  Heart Rhythm 12(7):1584-94
Publication list retrieved from NCBI using ImpactPubs

Leave a Reply